Anteris Technologies Global (AVR) said late Thursday that it has priced a US initial public offering of 14.8 million shares at $6.00 each.
The shares are expected to begin trading Friday on Nasdaq under the ticker "AVR." The company said it expects the offering to close Monday.
The Australian medical device maker also said it has given underwriters a 30-day option to purchase up to 2.2 million additional shares.
The company said the net proceeds from the offering, along with existing cash, will be used for development of its DurAVR transcatheter heart valve, as well as to prepare for and enroll in a study of the device for treating severe aortic stenosis and for other general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.